Article
10 Sep 2026
The Villages Health System $541.5 Million Settlement: A New Frontier In Medicare Advantage Risk Adjustment Enforcement
AUTHORS CONTENT
Article
04 Sep 2026
Back To Status Quo: Eleventh Circuit Upholds FCA’s Qui Tam Provisions Against Appointments Clause Challenge
Article
17 Aug 2026
DOJ's $46M Veloxis Settlement Signals Deeper Scrutiny Of Pharma Referral Arrangements
Article
23 Jul 2026
Preparing For The Pharma Fraud Enforcement Surge
Article
06 Jul 2026
DOJ Announces Record 2026 National Health Care Fraud Takedown: 455 Defendants, $6.5 Billion Alleged Fraud
Article
04 Jun 2026
DOJ Accelerates False Claims Act Enforcement: New Protocol Signals Faster Action On Benefits Fraud Whistleblower Cases
Article
18 May 2026
OIG Overhauls Corporate Integrity Agreements: What Healthcare Organizations Must Do Now
Article
02 Mar 2026
Federal Court Rules Documents Prepared Using Public AI Tools Not Protected By Attorney-Client Privilege
Article
13 Feb 2026
HHS-OIG Issues Medicare Advantage Industry Segment-Specific Compliance Program Guidance
Article
23 Jan 2026
False Claims Act Settlements, Judgments Top $6.8 Billion In 2025
Article
14 Jul 2025
Federal Agencies Intensify Focus On Healthcare Fraud Enforcement
Article
03 Feb 2025
HHS-OIG Issues Favorable Opinion On Drug Manufacturer's Free Genetic Testing, Counseling For Patients
Article
27 Jan 2025
DOJ Announces False Claims Act Settlements, Judgments Top $2.9 Billion In 2024
Article
26 Dec 2024
HHS-OIG Warns Against Suspect Payments Between Medicare Advantage Organizations And Healthcare Professionals
Article
23 Dec 2024
2023 Health Care Fraud And Abuse Control Program Report Reveals $3.4 Billion In Fraud Recovery
Article
16 Aug 2024
The Gloves Are Off: DOJ Whistleblower Pilot Program Set To Shore Up 'Gaps' In Private Payer Healthcare Enforcement
Article
21 May 2024
AHLA's Speaking Of Health Law: Private Equity In Health Care: Latest Trends And Developments
Article
18 Mar 2024
The Antitrust Investigator Will See You Now: What Healthcare And Pharma Should Expect In A World Of Enhanced Antitrust Scrutiny